Home  |  Contact

Cellosaurus H9 (CVCL_1240)

[Text version]

Cell line name H9
Synonyms HT clone H9; HT(H9); H 9; H-9
Accession CVCL_1240
Resource Identification Initiative To cite this cell line use: H9 (RRID:CVCL_1240)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Characteristics: Permissive for HIV-1 replication. Is accordingly used to isolate and propagate HIV-1 from the blood of patients with AIDS.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Anecdotal: For a number of years it was not known that H9 used by Gallo's lab to isolate HIV-1 (HTLV-III) was in fact a clone of Hut 78 from Minna's lab (PubMed=2567177). This created a controversy between the labs of Minna and Gallo (PubMed=2193399).
Discontinued: IZSLER; BS TCL 19; probable.
Derived from sampling site: Peripheral blood.
Sequence variations NRAS p.Gln61Lys (c.181C>A) (ClinVar=VCV000073058) (from parent cell line).
Homozygous for TP53 p.Arg196Ter (c.586C>T) (ClinVar=VCV000043589) (from parent cell line).
Genome ancestry Source: PubMed=30894373

Origin% genome
African4.91
Native American1.41
East Asian, North5.59
East Asian, South0
South Asian0
European, North61.37
European, South26.72
Disease Mycosis fungoides and Sezary syndrome (NCIt: C9265)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0337 (HuT 78)
Children:
CVCL_X680 (H9/HIV-2MVP-11971)CVCL_X681 (H9/HIV-2MVP-15132)CVCL_3514 (H9/HTLV-IIIB)
CVCL_X621 (H9/HTLV-IIICC)CVCL_X620 (H9/HTLV-IIIMN)CVCL_X619 (H9/HTLV-IIIRF)
CVCL_X610 (H9/SIVmac186)CVCL_D536 (H938)CVCL_U264 (RH9)
Sex of cell Male
Age at sampling 53Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ECACC; KCLB

Markers:
AmelogeninX,Y
CSF1PO11
D3S135815,16
D5S81811
D7S8208,11
D13S3178,12
D16S53911,12
FGA21,25
TH018,9
TPOX8,9
vWA14,15

Run an STR similarity search on this cell line
Web pages http://www.nibsc.org/Default.aspx?pageid=597&id=0001&theme=default
http://www.bmj.com/rapid-response/2011/10/30/cell-lines-hut102-and-hut78
http://www.cellresource.cn/fdetail.aspx?id=799
Publications

PubMed=2567177; DOI=10.1089/aid.1989.5.253
Mann D.L., O'Brien S.J., Gilbert D.A., Reid Y.A., Popovic M., Read-Connole E., Gallo R.C., Gazdar A.F.
Origin of the HIV-susceptible human CD4+ cell line H9.
AIDS Res. Hum. Retroviruses 5:253-255(1989)

PubMed=2193399; DOI=10.1126/science.2193399
Rubinstein E.
The untold story of HUT78.
Science 248:1499-1507(1990)

PubMed=1460674; DOI=10.1093/jnci/84.24.1922
Chen T.-R.
Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility.
J. Natl. Cancer Inst. 84:1922-1926(1992)

PubMed=8320746; DOI=10.1093/jnci/85.14.1168
Bunn P.A. Jr., Whang-Peng J., Gazdar A.F., Minna J.D., Carney D.N.
Karyotypic derivation of H9 cell line.
J. Natl. Cancer Inst. 85:1168-1169(1993)

PubMed=8127147
Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)

PubMed=17170727; DOI=10.1038/sj.leu.2404486
Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M., de Vos J., Macleod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M., Langerak A.W.
Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.
Leukemia 21:230-237(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections ATCC; HTB-176
CCTCC; GDC0031
ECACC; 85050301
ICLC; HTL05006
IZSLER; BS TCL 19
KCB; KCB 200418YJ
KCLB; 30176
NIH-ARP; 87-436
Cell line databases/resources CLDB; cl1556
CLDB; cl1557
CLDB; cl7167
CCLE; H9_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3142C0001000000031
Cell_Model_Passport; SIDM01251
Cosmic-CLP; 907043
DepMap; ACH-002240
LINCS_LDP; LCL-1144
Lonza; 910
TOKU-E; 3613
Ontologies BTO; BTO:0001944
CLO; CLO_0003581
CLO; CLO_0003612
EFO; EFO_0003045
Biological sample resources BioSample; SAMN03472731
Chemistry resources ChEMBL-Cells; CHEMBL3308402
ChEMBL-Targets; CHEMBL614806
GDSC; 907043
PharmacoDB; H9_439_2019
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1669836
Other Wikidata; Q54872230
Polymorphism and mutation databases Cosmic; 687842
Cosmic; 907043
Cosmic; 933542
Cosmic; 2301568
Cosmic; 2668295
Entry history
Entry creation04-Apr-2012
Last entry update02-Jul-2020
Version number26